Newsfeed : HIV Activists Fault South African Mother-Child Transmission Guidelines

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Newsfeed » January 2008

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 31, 2008

HIV Activists Fault South African Mother-Child Transmission Guidelines

In response to new South African treatment guidelines for the prevention of mother–child HIV transmission, the Treatment Action Campaign (TAC), an HIV/AIDS lobby group, has said that although the guidelines contain improvements, they fall short of World Health Organization recommendations, according to the South African financial daily newspaper Business Day/AllAfrica.com (allafrica.com, 1/31).

The guidelines were issued on January 25. They advise that all HIV-positive pregnant women be treated with two HIV drugs: AZT from the 28th week of pregnancy, and nevirapine during labor. Infants of HIV-positive mothers are recommended to receive a dose of nevirapine syrup and seven days of AZT. The guidelines also recommend that all pregnant women be tested for HIV and that all babies of HIV-positive mothers be screened for the virus at 6 weeks and 18 months.

The new guidelines do not, however, change the threshold for when expectant mothers should start long-term therapy. They say that mothers should be treated when their CD4 count falls below 200, as opposed to 350, the level that many AIDS activists are calling for.

The TAC said that post-delivery, HIV-positive women should be given a week of AZT and lamivudine, known as the “cover-the-tail strategy,” in order to decrease nevirapine resistance. It also expressed disappoint at the decision not to change the threshold for initiating antiretroviral therapy.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    andais
    Red House
    West Virginia


    zeze42
    Bay Area - Peninsula
    California


    max38man
    Chicago
    Illinois


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Is HIV/AIDS adequately portrayed in pop culture?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.